Chemotherapy as an adjuvant to cystectomy and for advanced urothelial cancer.
Because chemotherapy for metastatic transitional cell cancer has resulted in a high percentage of complete and partial responses, it is hoped that further research will lead to improved long-term cure rates in patients with locally invasive disease. This is especially true in those instances in which chemotherapy can be combined as an adjunct to cystectomy and/or radiation therapy.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D001743:Urinary Bladder / Q000601:surgery*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014801:Vitamin A / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D014801:Vitamin A; D003520:Cyclophosphamide; D002945:Cisplatin; D008727:Methotrexate